Tislelizumab (Baizean)

Note: Tislelizumab is approved in China for multiple indications, but does not appear to have a brand name at this time.

Mechanism of action

From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.

Diseases for which it is used

• Bladder cancer
• Esophageal squamous cell carcinoma
• Hepatocellular carcinoma
• Classical Hodgkin lymphoma
• Nasopharyngeal carcinoma
• Non-small cell lung cancer
  • Non-small cell lung cancer, nonsquamous
  • Non-small cell lung cancer, squamous

Also known as

• Code name: BGB-A317